CN208877429U - A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest - Google Patents
A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest Download PDFInfo
- Publication number
- CN208877429U CN208877429U CN201820311126.4U CN201820311126U CN208877429U CN 208877429 U CN208877429 U CN 208877429U CN 201820311126 U CN201820311126 U CN 201820311126U CN 208877429 U CN208877429 U CN 208877429U
- Authority
- CN
- China
- Prior art keywords
- aurantiin
- hydroxyapatite
- gelatine microsphere
- compound rest
- microballoon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010022355 Fibroins Proteins 0.000 title claims abstract description 44
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 39
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 title claims abstract description 26
- -1 hydroxyapatite compound Chemical class 0.000 title claims abstract description 12
- 229920000159 gelatin Polymers 0.000 claims abstract description 43
- 235000019322 gelatine Nutrition 0.000 claims abstract description 43
- 239000004005 microsphere Substances 0.000 claims abstract description 41
- 239000001828 Gelatine Substances 0.000 claims abstract description 40
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 28
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 25
- 230000007547 defect Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 22
- 230000001788 irregular Effects 0.000 claims description 4
- 239000002131 composite material Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000002045 lasting effect Effects 0.000 abstract description 3
- 230000011164 ossification Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 235000001759 Citrus maxima Nutrition 0.000 description 8
- 244000276331 Citrus maxima Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001148782 Davallia Species 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008236 heating water Substances 0.000 description 3
- 229940059936 lithium bromide Drugs 0.000 description 3
- 230000004072 osteoblast differentiation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000000278 osteoconductive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010059600 Donor site complication Diseases 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- VWDWKYIASSYTQR-YTBWXGASSA-N sodium;dioxido(oxo)azanium Chemical compound [Na+].[O-][15N+]([O-])=O VWDWKYIASSYTQR-YTBWXGASSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The utility model discloses a kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rests, including silk fibroin bracket, hydroxyapatite, gelatine microsphere, the Hydroxyapatite-Supported is in silk fibroin bracket, the silk fibroin bracket is coated on gelatine microsphere surface, the gelatine microsphere at least one, load has aurantiin on the gelatine microsphere, the sphere diameter of the gelatine microsphere is 20-40 μm, aurantiin/gelatine microsphere/nanometer hydroxyapatite/fibroin protein composite bracket provided by the utility model, with good rheological characteristic, easy plasticity, biomechanical strength, and preferably promote bone formation performance, so as to be suitable for different bone defect area, and effect is lasting, with stronger bone tissue reparation ability, convenient for large-scale promotion application.
Description
Technical field
The utility model relates to tissue engineering technique fields, and in particular to a kind of aurantiin microballoon fibroin albumen/hydroxyl phosphorus
Lime stone compound rest.
Background technique
Three big elements one of of the biomaterial scaffolds as regenerative medicine, play key player during bone remoulding,
Therefore it is usually used in treating OVF under study for action.In numerous biomaterials, hydroxyapatite due to its preferable osteoconductive nature with
And the mineralization process and structure similar with bone tissue, it is concerned in terms of bone defect regenerates research.Fibroin albumen is a kind of tool
There are higher mechanical strength, controllable biodegradable ability, good biocompatibility and the natural biological height being easily handled
Polymers.Fibroin albumen and hydroxyapatite are fabricated to compound rest using modern science and technology, the two advantage can be collected in one
Body is a kind of reason that can be used for OVF treatment the shortcomings that also avoiding the low carrying pressure of traditional material, rejection, can not degrade
Think, novel tissue engineering material.In recent years, traditional Chinese medicine embodies its unique advantage, the Chinese medicine rhizome of davallia in terms of preventing and treating OVF
With The strong bone of kidney tonifying, the effect of activating microcirculation and removing stasis medicinal, be conventionally used to facilitate union in clinic, aurantiin be the rhizome of davallia mainly effectively at
/ mono-, in promoting bone growing, promotes angiogenesis, inhibits Inflammatory effects significant.
Polymethyl methacrylate is common implantation material, although being capable of providing enough support strengths and cementation,
But there is also some obvious disadvantages: cannot be degraded and absorbed in vivo, poor biocompatibility, inactive, when polymerization releases
The heat of amplification quantity, unconverted monomer are toxic etc., and resulting in, some serious complication can usually occur in clinical application.In order to
The quality of life of patient is promoted, the biomaterial that finding, there is good biocompatibility can simultaneously provide enough support strengths is existing rank
The hot spot of section research.There is good absorbability, biocompatibility, bone to pass for autologous bone, calcium sulfate, calcium phosphate, calcium silicates etc.
The features such as property led, thus become the focus of numerous researchs.Autologous bone transplanting is still the current goldstandard material for promoting union
Material, but the autologous bone limited amount because that can transplant, bone donor site complication due to be restricted.Hydroxyapatite
(hydroxyapatite, HAp) is using calcium phosphate as main component, because it is with preferable osteoconductive nature, and and biological bone
Tissue mineralization process is similar, makees with the integrin superfamily Surface molecular interactions of osteoprogenitor cells etc. with certain self-bone grafting
With, therefore be concerned in regenerative medicine field as ideal stent.Research confirms that in vivo, HAp can promote the outer base of rat cell
Matter provides collagen stroma into the cell, plays a significant role in the maintenance of cell migration, growing multiplication, differentiation and Cell Homeostasis, from
And promote osteanagenesis；In vitro, HAp and stem cell interaction can induce osteogenic factor (such as Cabf1 or Runx) release
To promote stem cells hyperplasia and Osteoblast Differentiation.But the disadvantage that HAp compression strength is low simultaneously, brittleness is big, absorptivity is slower etc.
Largely affect its application clinically.It therefore, is main with HA p in order to preferably meet clinical demand
Ingredient, the mode for improving performance with other one or more Material claddings become research hotspot in recent years.Fibroin albumen (silk
Fibro in, SF) it is that a kind of natural polymer fibrin structure extracted from silk is similar to bone collagen, without obvious anti-
Originality is implanted into bone and apparent rejection does not occur, has good biocompatibility, and is conducive to the heavy of calcium salt
Product.The study found that SF can stimulate the high expression of the Osteoblast Differentiation factor, promote the early and late Osteoblast Differentiation of osteoblast, but body
Interior Germicidal efficacy only finds the environment of offer host cell proliferation, does not find apparent bon e formation.Studies have shown that various concentration silk
Fibroin carries out mixing the compression strength that can increase composite material in various degree, and the more simple HAp of SF/HAp compound rest with HAp
Bracket increases osteoblastic proliferation and differentiation rate, promotes osteanagenesis by cell-fret signal access.Therefore, using HAp/SF
Treating OVF is ideal compound rest.
Utility model content
The purpose of the utility model is to overcome provide a kind of by rhizome of davallia shaddock in place of the shortcomings of the prior art
Skin glycosides application gelatine microsphere is wrapped up and is carried in SF/HAp compound rest, for treating the compound of Osteoporotic vertebral fracture
Bracket.
To achieve the above object, the technical solution taken:
A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest, including silk fibroin bracket, hydroxy-apatite
Stone, gelatine microsphere, for the Hydroxyapatite-Supported in silk fibroin bracket, the silk fibroin bracket is coated on gelatine microsphere
Surface, the gelatine microsphere at least one, on the gelatine microsphere load have aurantiin.
Preferably, the sphere diameter of the gelatine microsphere is 20-40 μm.
Preferably, the fibroin albumen, hydroxyapatite, gelatine microsphere, aurantiin mass ratio be (7-20): (1-
2): (1-2): (2-4).
Preferably, the shape of the compound rest is irregular geometry.
Preferably, the shape of the compound rest is the geometry of rule.
Preferably, the shape of the compound rest is cylindrical shape.
Preferably, the compound rest is consistent with the structure in bone defect area to be repaired.
The utility model has the beneficial effects that
1, aurantiin/gelatine microsphere/nanometer hydroxyapatite/fibroin protein composite bracket provided by the utility model, tool
There are good rheological characteristic, easy plasticity, biomechanical strength and preferably promotees bone formation performance, it is each so as to be suitable for shape
Different bone defect area, and effect is lasting, has stronger bone tissue reparation ability, is convenient for large-scale promotion application.
2, the shape of the compound rest of the utility model can be the solid structure of rule, such as cylindrical type or irregular
Solid structure, it is consistent with the structure in bone defect area to be repaired, so as to be suitable for different bone defect area, silk
Fibroin bracket, which mix with hydroxyapatite, to increase the compression strength of composite material in various degree, to increase Biological Strength
Intensity is learned, biodegradability that gelatine microsphere has, biocompatibility, are rare carrier materials, micro- using gelatin
Ball wraps up aurantiin, has the function of Drug controlled release, extends curative effect of medication, to improve the stability of drug, reduces medicine
The adverse reaction of object, while its own with anti-inflammatory effect, rhizome of davallia aurantiin gelatine microsphere is carried on SF/HAp and answered by us
Bracket is closed, the healing of OVF can be further promoted and enhances the mechanical strength of fractured vertebral body.
Detailed description of the invention
Fig. 1 is the compound rest structural schematic diagram of the utility model；
Fig. 2 is the utility model observation structure figure under 100um scanning electron microscope；
Fig. 3 is the utility model observation structure figure under 20um scanning electron microscope.
Specific embodiment
The utility model is further described in detail with reference to the accompanying drawing, these attached drawings are simplified signal
Figure, only illustrates the basic structure of the utility model, the direction of this specific implementation is using the direction Fig. 1 as standard in a schematic way.
The utility model discloses a kind of aurantiin/gelatine microsphere/nanometer hydroxyapatite/fibroin protein composite bracket,
Including silk fibroin bracket 1, hydroxyapatite 2, gelatine microsphere 3, wherein hydroxyapatite 2 is carried on silk fibroin bracket 1
Interior, silk fibroin bracket 1 is coated on 3 surface of gelatine microsphere, gelatine microsphere 3 at least one, the sphere diameter of gelatine microsphere 3 is 20-40
μm, on gelatine microsphere 3 load have aurantiin, wherein fibroin albumen, hydroxyapatite, gelatine microsphere, aurantiin mass ratio be
(7-20): (1-2): (1-2): (2-4).
The shape of the compound rest of the utility model can be the solid structure of rule, such as cylindrical type or irregular several
What body structure, as shown in Figure 1, it is consistent with the structure in bone defect area to be repaired, so as to be suitable for different bone
Defective region, silk fibroin bracket 1 carry out mixing the compression strength that can increase composite material in various degree with hydroxyapatite 2, from
And increasing biomechanical strength, biodegradability that gelatine microsphere has, biocompatibility, are rare carrier materials
Material wraps up aurantiin using gelatine microsphere 3, has the function of Drug controlled release, extends curative effect of medication, to improve drug
Stability, reduces the adverse reaction of drug, while its own is with anti-inflammatory effect, we are by rhizome of davallia aurantiin gelatine microsphere 3
It is carried on SF/HAp compound rest, can further promote the healing of OVF and enhances the mechanical strength of fractured vertebral body.
Aurantiin/gelatine microsphere/nanometer hydroxyapatite/fibroin protein composite bracket provided by the utility model, has
Good rheological characteristic, easy plasticity, biomechanical strength and preferably promote bone formation performance, it is different so as to be suitable for
Bone defect area, and effect is lasting, has stronger bone tissue reparation ability, is convenient for large-scale promotion application.
It can be seen that by scanning electron microscope (SEM) photograph Fig. 2, Fig. 3, fibroin albumen (SF) hydroxyapatite (HA) bracket is coated on shaddock ped
Glycosides/gelatine microsphere microsphere surface.
Load rhizome of davallia microballoon fibroin albumen/hydroxyapatite compound rest preparation method of the utility model, including
Following steps:
(1) preparation of silk fibroin protein solution
It after silk cocoon is shredded, is placed in the sodium bicarbonate solution that concentration is 0.5wt%, 0.5h is boiled in heating, then uses
Deionized water cleaning, removes colloid, repeats this step three times.The fibroin albumen of colloid will be removed, is placed in 50 DEG C of baking oven
Drying for 24 hours, removes the moisture in fibroin albumen.
It by the fibroin albumen after drying, shreds, is subsequently placed in the lithium-bromide solution that concentration is 9.3mol/L, wherein silk
The ratio of fibroin and lithium-bromide solution is 1:10 (m:v), 60 DEG C of heating water bath 5h.Lithium bromide is dissolved completely in fibroin albumen
After in solution, by obtained mixed solution, it is placed in the bag filter that molecular cut off is 10KD, then uses deionized water
In, it dialyses under room temperature, changing water frequency is that the daily water that changes is primary, and dialysis time is three days.It is molten by what is obtained after dialysis
Liquid carries out centrifugation 10min in 5000rpm, takes supernatant, repeats the step 3 time, and can obtain concentration is that 3.5wt%SF is molten
Liquid, and be placed in 4 degrees Celsius of refrigerator, it saves backup.When preparing SF when needing, then suitable solution is poured into mold,
It is subsequently placed into -20 DEG C of refrigerator freezings to stay overnight, is finally putting into freeze drier and is lyophilized, be freeze-dried condition are as follows: -60 DEG C/
For 24 hours, it can be prepared by SF bracket.
(2) preparation of nanometer hydroxyapatite (Hydroxyapatite, HA)
The ammonium dibasic phosphate aqueous solution of 100ml 0.3mol/L is added drop-wise in the calcium nitrate solution of 100ml 0.5mol/L,
During dropwise addition, mechanical stirring, mixing speed 400rpm, and at the same time in 60 DEG C of heating water bath 2h.It is being stirred to react process
In, the pH value of reaction solution is maintained 10 by the way that ammonium hydroxide is added dropwise；After reaction, it is aged for 24 hours, then passes through at room temperature
5000rpm is centrifuged 10min and collects, and is cleaned 5 times with deionized water.Finally, the nano particle that will be collected into, -60 DEG C/
It under conditions of for 24 hours, is freeze-dried, nano-hydroapatite particles (HA) can be obtained.
(3) shaddock ped it is sweet/preparation of gelatine microsphere compound
0.1g sorbitol anhydride oleate (Span-80, Span80) is added in the flask for filling 100ml vegetable oil, in
60 DEG C, 400rpm heating water bath stirring 0.5h, after mixing；10ml 10wt% aqueous gelatin solution is added dropwise to vegetable oil
In, after persistently stirring 3h, mixed solution is transferred to ice bath, continues to stir 30min.Then 0.1ml 25wt% penta 2 is added
Aldehyde aqueous solution continues after stirring 2h, 4 DEG C of 30ml of acetone is added, and after stirring 30min, stands, and it is micro- just to obtain gelatin for filtering
Ball；It by microballoon bubble in 10ml acetone, is placed in 4 DEG C of refrigerator, solidification impregnates 30min/ with 1mol/L amion acetic acid afterwards for 24 hours
25 DEG C, remove unreacted glutaraldehyde.Then it is centrifuged 10min in 5000rpm, taking precipitate is alternately washed with ethyl alcohol and isopropanol
Sediment is washed, cleaning 3 times is alternately repeated.The gelatine microsphere obtained after cleaning is placed in deionized water, in 4 DEG C/soaked overnight.
Finally, being freeze-dried, gelatine microsphere is obtained.The gelatine microsphere partial size of the present embodiment is 25 μm.
Be dissolved in the shaddock ped of 0.5g is sweet in the ethyl alcohol of 1ml, obtain the shaddock ped that concentration is 0.5g/ml it is sweet/ethanol solution.With
Afterwards toward the gelatine microsphere of 10mg, the shaddock ped for being added dropwise 40ul 0.5g/ml is sweet/ethanol solution, it is then placed into 4 DEG C, overnight.Most
Afterwards, be freeze-dried, can obtain shaddock ped it is sweet/gelatine microsphere (NG/GMs) compound.
(4) shaddock ped it is sweet/gelatine microsphere/nanometer hydroxyapatite/fibroin protein composite bracket (NG/GMs/HA/SF) system
It is standby
It after 5mgHA, 5mgNG/GMs are mixed with 1ml 3.5wt%SF solution, is injected in 48 orifice plates, then, by the sample
Product are freeze-dried for 24 hours at -60 DEG C, can obtain NG/GMs/HA/SF compound rest.
It as shown in Figures 2 and 3, is the NG/GMs/HA/SF compound rest of the utility model respectively in 100um and 20um
The structure observed under scanning electron microscope.
The above is only the preferred embodiment of the utility model only, is not intended to limit the utility model, all at this
Within the spirit and principle of utility model, any modification, equivalent substitution, improvement and etc. done should be included in the utility model
Within the scope of protection.
Claims (6)
1. a kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest, which is characterized in that including silk fibroin bracket,
Hydroxyapatite, gelatine microsphere, in silk fibroin bracket, the silk fibroin bracket is coated on the Hydroxyapatite-Supported
Gelatine microsphere surface, the gelatine microsphere at least one, on the gelatine microsphere load have aurantiin.
2. aurantiin microballoon fibroin albumen/hydroxyapatite compound rest according to claim 1, which is characterized in that institute
The sphere diameter for stating gelatine microsphere is 20-40 μm.
3. aurantiin microballoon fibroin albumen/hydroxyapatite compound rest according to claim 1, which is characterized in that institute
The shape for stating compound rest is irregular geometry.
4. aurantiin microballoon fibroin albumen/hydroxyapatite compound rest according to claim 1, which is characterized in that institute
The shape for stating compound rest is the geometry of rule.
5. aurantiin microballoon fibroin albumen/hydroxyapatite compound rest according to claim 1, which is characterized in that institute
The shape for stating compound rest is cylindrical shape.
6. aurantiin microballoon fibroin albumen/hydroxyapatite compound rest according to claim 1, which is characterized in that institute
It is consistent with the structure in bone defect area to be repaired to state compound rest.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820311126.4U CN208877429U (en) | 2018-03-06 | 2018-03-06 | A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820311126.4U CN208877429U (en) | 2018-03-06 | 2018-03-06 | A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN208877429U true CN208877429U (en) | 2019-05-21 |
Family
ID=66492073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201820311126.4U Expired - Fee Related CN208877429U (en) | 2018-03-06 | 2018-03-06 | A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN208877429U (en) |
-
2018
- 2018-03-06 CN CN201820311126.4U patent/CN208877429U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Venkatesan et al. | Alginate composites for bone tissue engineering: A review | |
| CN105641753B (en) | A kind of 3D printing biodegradable stent of the achievable blood vessel transfer of compound rhBMP-2 | |
| CN108159502A (en) | Aurantiin microballoon fibroin albumen/hydroxyapatite compound rest and preparation method thereof | |
| Goh et al. | Alginates as a useful natural polymer for microencapsulation and therapeutic applications | |
| CN100546661C (en) | A kind of preparation method of in situ pore-forming self-setting calcium phosphate composite tissue engineering scaffold | |
| US9925301B2 (en) | Methods of producing and using silk microfibers | |
| CN111097068B (en) | Bionic hydroxyapatite powder/gelatin/sodium alginate composite 3D printing support and preparation method thereof | |
| CN108310470B (en) | Sustained and controlled release oxygen microsphere, preparation method and application thereof | |
| CN101934095B (en) | Injectable strengthened phosphate lime/hydrogel microcapsule tissue engineering bone as well as preparation method and application thereof | |
| CN103877617A (en) | Injectable silk fibroin-alginate double cross-linking hydrogel and preparation method and use method thereof | |
| CN102008752B (en) | Porous biphasic calcium phosphate biological scaffold with nano hydroxyapatite coating and preparation method thereof | |
| CN103083723B (en) | Collagen/nano-crystalline cellulose skin regenerative material, preparation method and application thereof | |
| CN101264341A (en) | Three-dimensional porous tissue engineering bracket material, preparation and application thereof | |
| CN102218160A (en) | Preparation and application of nerve tissue matrix derived tissue engineering scaffold material | |
| Wang et al. | Local delivery of BMP-2 from poly (lactic-co-glycolic acid) microspheres incorporated into porous nanofibrous scaffold for bone tissue regeneration | |
| CN109675119A (en) | A kind of artificial dermis and preparation method thereof for chronic wound treatment | |
| CN104368046B (en) | A kind of fiber reinforcement type medicine carrying hydrogel artificial cornea skirt hanger and preparation method thereof | |
| CN105521525A (en) | Porous composite scaffold for bone tissue engineering and preparation method therefor | |
| CN102552985B (en) | Silk fibroin/calcium phosphate bone cement-based porous composite material and preparation method thereof | |
| CN208877429U (en) | A kind of aurantiin microballoon fibroin albumen/hydroxyapatite compound rest | |
| CN108187139A (en) | It is a kind of for drug-loaded artificial bone material of repairing bone defect and preparation method thereof | |
| CN102580145B (en) | Method for preparing phosphomycin calcium/hexagonal mesoporous silicon/poly glycolide-co-lactide (PLGA) bone tissue stent | |
| CN115998958A (en) | Bone tissue engineering scaffold with slow release function and preparation method and application thereof | |
| CN113350573B (en) | Porous microsphere adhesive with osteoinductive capacity and preparation method thereof | |
| KR100482651B1 (en) | Tissue Engineered Natural/Synthetic Hybrid Scaffolds and its Manufactory Methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190521 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |